OnKure Therapeutics, Inc. (OKUR) - Dilution Analysis

10-Q filing | 40.4M shares outstanding

10-K filing | 13.5M shares outstanding

POS AM filing: This prospectus relates to the resale by the selling securityholders named in this prospectus of 1,507,685 shares of Class A common stock that were sold and issued to the selling securityholders in a private placement on October 4, 2024.

S-3 filing: This S-3 filing from OnKure Therapeutics, Inc. outlines a shelf offering for various securities, including Class A Common Stock, Preferred Stock, Debt Securities, Depositary Shares, Subscription Rights, and Purchase Contracts, with an aggregate offering price not exceeding $200,000,000.

10-Q filing | 13.5M shares outstanding

10-Q filing | 13.4M shares outstanding

POS AM filing: This prospectus relates to the resale by certain selling securityholders of 2,938,005 shares of Class A Common Stock issued in a private placement on October 4, 2024.

10-K filing | 12.7M shares outstanding

10-Q filing | 12.7M shares outstanding

S-1 filing: This S-1 filing relates to the resale of 2,938,005 shares of Class A Common Stock issued in a private placement on October 4, 2024 by selling securityholders.

10-Q filing | 33.4M shares outstanding

10-Q filing | 33.4M shares outstanding

10-K filing | 30.7M shares outstanding

10-Q filing | 33.8M shares outstanding

S-3 filing: The company is filing an S-3 to offer up to $300,000,000 of any combination of common stock, preferred stock, debt securities, and warrants.

8-K filing: Reneo Pharmaceuticals, Inc. repurchased 576,443 shares of its common stock from vTv Therapeutics LLC for approximately $4.4 million at a price of $7.64 per share in a private, non-underwritten transaction. ($4.4M proceeds)

10-Q filing | 33.8M shares outstanding

S-3 filing: This prospectus relates to the resale from time to time of up to 625,000 shares of our common stock by the selling stockholders identified in this prospectus, all of which were issued by us in a private placement on May 9, 2023.

10-Q filing | 33.7M shares outstanding

10-K filing | 24.5M shares outstanding

10-Q filing | 24.5M shares outstanding

10-Q filing | 24.5M shares outstanding

10-Q filing | 24.5M shares outstanding

S-3 filing: The company intends to offer a combination of common stock, preferred stock, and debt securities up to a total of $200,000,000 from time to time.

10-K filing | 2.1M shares outstanding

10-Q filing | 2.1M shares outstanding

10-Q filing | 2.1M shares outstanding

10-Q filing | 2.1M shares outstanding

S-1/A filing: This is an S-1/A filing related to an offering of common stock, including firm shares and optional shares, underwritten by Jefferies, SVB Leerink, and Piper Sandler, with details regarding representations, warranties, covenants, and closing conditions.

S-1 filing: This S-1 filing outlines the terms for a proposed initial public offering of common stock. It also details previous private placements of Series A convertible preferred stock to various entities. It includes the option for underwriters to purchase additional shares, and prohibits sales of similar securities.